Galectin-3 Expression in High-Risk HPV-Positive and Negative Head & Neck Squamous Cell Carcinomas and Regional Lymph Node Metastases

Abstract

Despite higher stages at presentation, patients with high-risk (HR) HPV-related (HPV+) head and neck squamous cell carcinomas (HNSCCs) have better survival rates compared to those with non-HPV-related (HPV−) disease. However, significant comorbidity and the number of patients who suffer failed treatment, recurrent disease, late metastasis, and death are increasing along with the incidence of HPV+ HNSCC. A cytotoxic T-cell-dependent immune response is required to clear these antigenic cancers. This provides a unique opportunity to employ immune modulators in therapy. Galectin-3 (Gal-3) is a lectin and glycoprotein involved in numerous immunosuppressive functions. Inhibitors are currently under clinical investigation for various diseases. Gal-3 expression was evaluated in HR-HPV+ and HPV− HNSCCs and regional lymph node metastases by tissue microarray. HR-HPV+ cases were more likely to be Gal-3-positive (Gal+) [50% (14/28)] than HPV− cases [18% (9/50), p = 0.004]. No difference in the number of Gal+ cases was identified between primary [30% (16/53)] and metastatic [28% (7/25)] cancers (p = 1); 53% (9/17) of primary HPV+ cancers were Gal+ and 45% (5/11) of metastatic HPV+ cancers were Gal+ (p = 1). Nineteen percent (7/36) of primary HPV− cancers were Gal+ and 14% (2/14) of metastatic HPV− cancers were Gal+ (p = 1). Gal-3 positivity was observed in a subset of HNSCC, suggesting a potential role for therapeutic inhibition in this tumor type. The significantly higher rates of expression seen in HR-HPV+ versus HPV− HNSCC suggest particular promise in the setting of HPV infection. The relatively consistent Gal-3 expression rates observed between metastatic and primary tumors argues against progressive Gal-3 expression in metastasis.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Leemans CR, Braakhuis BJM, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11:9–22.

    CAS  Article  Google Scholar 

  2. 2.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2015;66:7–30.

    Article  Google Scholar 

  3. 3.

    Marur S, Forastiere AA. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2016;91:386–96.

    Article  Google Scholar 

  4. 4.

    Lee DW, Anderson ME, Wu S, Lee JH. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer. Arch Otolaryngol Head Neck Surg. 2008;134:1316–23.

    Article  Google Scholar 

  5. 5.

    Gooi Z, Chan JYK, Fakhry C. The epidemiology of the human papillomavirus related to oropharyngeal head and neck cancer. Laryngoscope. 2016;126:894–900.

    Article  Google Scholar 

  6. 6.

    Marur S, D’Souza G, Westra WH, Forastiere A. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11:781–9.

    Article  Google Scholar 

  7. 7.

    Koch WM. Clinical features of HPV-related head and neck squamous cell carcinoma: presentation and work-up. Otolaryngol Clin North Am. 2012;45:779–93.

    Article  Google Scholar 

  8. 8.

    Marklund L, Hammarstedt L. Impact of HPV in oropharyngeal cancer. J Oncol. 2011;2011:509036.

    Article  Google Scholar 

  9. 9.

    O’Rorke MA, Ellison MV, Murray LJ, Moran M, James J, Anderson LA. Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. Oral Oncol. 2012;48:1191–201.

    Article  Google Scholar 

  10. 10.

    Ruzevick J, Olivi A, Westra WH. Metastatic squamous cell carcinoma to the brain: an unrecognized pattern of distant spread in patients with HPV-related head and neck cancer. J Neurooncol. 2013;112:449–54.

    CAS  Article  Google Scholar 

  11. 11.

    Spanos WC, Nowicki P, Lee DW, Hoover A, Hostager B, Gupta A, et al. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg. 2009;135:1137–46.

    Article  Google Scholar 

  12. 12.

    Williams R, Lee DW, Elzey BD, Anderson ME, Hostager BS, Lee JH. Preclinical models of HPV+ and HPV− HNSCC in mice: an immune clearance of HPV+ HNSCC. Head Neck. 2009;31(7):911–8.

    Article  Google Scholar 

  13. 13.

    Krupar R, Robold K, Gaag D, Spanier G, Kreutz M, Renner K, et al. Immunologic and metabolic characteristics of HPV-negative and HPV-positive head and neck squamous cell carcinomas are strikingly different. Virchows Arch. 2014;465:299–312.

    CAS  Article  Google Scholar 

  14. 14.

    Allen CT, Clavijo PE, Van Waes C, Chen Z. Anti-tumor immunity in head and neck cancer: understanding the evidence, how tumors escape and immunotherapeutic approaches. Cancers (Basel). 2015;7:2397–414.

    CAS  Article  Google Scholar 

  15. 15.

    Farhad M, Rolig AS, Redmond WL. The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment. Oncoimmunology. 2018;7:e1434467.

    Article  Google Scholar 

  16. 16.

    Kindt N, Journe F, Ghanem GE, Saussez S. Galectins and carcinogenesis: their role in head and neck carcinomas and thyroid carcinomas. Int J Mol Sci. 2017;18:2745.

    Article  Google Scholar 

  17. 17.

    Wang LP, Chen SW, Zhuang SM, Li H, Song M. Galectin-3 accelerates the progression of oral tongue squamous cell carcinoma via a Wnt/β-catenin-dependent pathway. Pathol Oncol Res. 2013;19(3):461–74.

    Article  Google Scholar 

  18. 18.

    Weber M, Büttner-Herold M, Distel L, Ries J, Moebius P, Preidl R, et al. Galectin 3 expression in primary oral squamous cell carcinomas. BMC Cancer. 2017;17:906.

    Article  Google Scholar 

  19. 19.

    Wehrhan F, Büttner-Herold M, Distel L, Ries J, Moebius P, Preidl R, et al. Galectin 3 expression in regional lymph nodes and lymph node metastases of oral squamous cell carcinomas. BMC Cancer. 2018;18:823.

    Article  Google Scholar 

  20. 20.

    Mesquita JA, Queiroz LMG, Silveira ÉJD, Gordon-Nunez MA, Godoy GP, Nonaka CFW, et al. Association of immunoexpression of the galectins-3 and -7 with histopathological and clinical parameters in oral squamous cell carcinoma in young patients. Eur Arch Oto-Rhino-Laryngol. 2016;273:237–43.

    Article  Google Scholar 

  21. 21.

    Punt S, Thijssen VL, Vrolijk J, De Kroon CD, Gorter A, Jordanova ES. Galectin-1, -3 and -9 expression and clinical significance in squamous cervical cancer. PLoS ONE. 2015;10:e0128119.

    Article  Google Scholar 

  22. 22.

    Vuong L, Kouverianou E, Rooney CM, McHugh BJ, Howie SEM, Gregory CD, et al. An orally active galectin-3 antagonist inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade. Cancer Res Cancer Res. 2019;79:1480–92.

    CAS  Article  Google Scholar 

  23. 23.

    Coppock JD, Lee JH. mTOR, metabolism, and the immune response in HPV-positive head and neck squamous cell cancer. World J Otorhinolaryngol Neck Surg. 2016;2:76–83.

    Article  Google Scholar 

Download references

Acknowledgments

The authors would like to acknowledge and thank the University of Virginia Biorepository & Tissue Research Facility for their skill and expertise in the construction of the tissue microarray and performance of the in situ hybridization and immunohistochemical assays used in this study.

Funding

No funding obtained.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Joseph D. Coppock.

Ethics declarations

Conflict of interest

No conflict of interest to disclose.

Ethical Approval

This work was approved by the Institutional Review Board of the University of Virginia (IRB #13310).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Coppock, J.D., Mills, A.M. & Stelow, E.B. Galectin-3 Expression in High-Risk HPV-Positive and Negative Head & Neck Squamous Cell Carcinomas and Regional Lymph Node Metastases. Head and Neck Pathol (2020). https://doi.org/10.1007/s12105-020-01195-3

Download citation

Keywords

  • Galectin 3
  • Head and neck cancer
  • Oropharyngeal cancer
  • Squamous cell carcinoma
  • Human papilloma virus
  • Metastasis